New South Wales Public Health Bulletin New South Wales Public Health Bulletin Society
Supporting public health practice in New South Wales

The effectiveness of harm reduction in preventing HIV among injecting drug users

Alex Wodak A C and Lisa Maher B

A Alcohol and Drug Service, St Vincent’s Hospital, Darlinghurst NSW

B National Centre in HIV Epidemiology and Clinical Research, Darlinghurst NSW

C Corresponding author. Email:

NSW Public Health Bulletin 21(4) 69-73
Published: 27 May 2010


There is now compelling evidence that harm reduction approaches to HIV prevention among injecting drug users are effective, safe and cost-effective. The evidence of effectiveness is strongest for needle and syringe programs and opioid substitution treatment. There is no convincing evidence that needle and syringe programs increase injecting drug use. The low prevalence (~1%) of HIV among injecting drug users reflects the early adoption and rapid expansion of harm reduction in Australia. Countries that have provided extensive needle and syringe programs and opioid substitution treatment appear to have averted an epidemic, stabilised or substantially reduced the prevalence of HIV among injecting drug users. However, despite decades of vigorous advocacy and scientific evidence, the global coverage of needle and syringe programs and opioid substitution treatment falls well short of the levels required to achieve international HIV control.


[1]  Stimson GV1989Syringe-exchange programmes for injecting drug users (Editorial review).AIDS325360doi:10.1097/00002030-198905000-00001Pubmed Abstract

[2]  International Harm Reduction Association. Position Statement on Harm Reduction. In: International Harm Reduction Association. IHRA Website. 2005. London: Komodo CMS. Available at: (Cited 4 March 2010.)

[3]  World Health Organization (SEARO & WPRO), United Nations Office on Drugs and Crime. HIV/AIDS care and treatment for people who inject drugs in Asia and the Pacific: an essential practice guide. Geneva: WHO Press; 2008. Available at: (Cited 4 March 2010.)

[4]  World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Program on HIV/AIDS. Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: World Health Organization; 2009. Available at: (Cited 4 March 2010.)

[5]  Wodak ACooney A2006Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence.Subst Use Misuse416–7777813doi:10.1080/10826080600669579Pubmed Abstract

[6]  General Accounting Office. Needle Exchange Programs: research suggests promise as an AIDS prevention strategy. Washington DC: United States Government Printing Office; 1993.

[7]  National Commission on AIDS. The twin epidemics of substance use and HIV. Washington DC: United States Government Printing Office; 1991.

[8]  Lurie P, Reingold AL, editors. The public health impact of needle exchange programs in the United States and abroad, Vol. 1. Atlanta: Centers for Disease Control and Prevention; 1993.

[9]  Office of Technology Assessment of the US Congress. The effectiveness of AIDS prevention efforts. Washington DC: United States Government Printing Office; 1995.

[10]  National Institutes of Health Consensus Panel. Interventions to prevent HIV risk behaviours. Bethesda: National Institutes Health; 1997.

[11]  Satcher D. Evidence-based findings on the efficacy of syringe exchange programs: an analysis of the scientific research completed since April 1998. Washington DC: United States Department of Health and Human Services; 2000.

[12]  Institute of Medicine of the National Academy of Science. No time to lose: getting more from HIV prevention. Washington DC: National Academies Press; 2001.

[13]  Committee on the Prevention of HIV Infection among Injecting Drug Users in High-Risk Countries (Board on Global Health, Institute of Medicine of the National Academies). Preventing HIV infection among injecting drug users in high risk countries: an assessment of the evidence. Washington DC: National Academies Press; 2006. Available at: (Cited 4 March 2010.)

[14]  Thomas DLAstemborski JRai RMAnania FASchaeffer MGalai Net al.2000The natural history of hepatitis C virus infection: host, viral, and environmental factors.JAMA2844506doi:10.1001/jama.284.4.450Pubmed Abstract

[15]  Moaven LDCrofts NLocarnini SA1993Hepatitis C virus infection in Victorian injecting drug users in 1971.Med J Aust1588574Pubmed Abstract

[16]  Des Jarlais DCPerlis TArasteh KTorian LVBeatrice SMilliken Jet al.2005HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services.Am J Public Health958143944doi:10.2105/AJPH.2003.036517

[17]  Bonell CHargreaves JStrange VPronyk PPorter J2006Should structural interventions be evaluated using RCTs? The case of HIV prevention.Soc Sci Med635113542doi:10.1016/j.socscimed.2006.03.026Pubmed Abstract

[18]  Holmes DPerron AO’Byrne P2006Evidence, virulence, and the disappearance of nursing knowledge: a critique of the evidence-based dogma.Worldviews Evid Based Nurs3395102doi:10.1111/j.1741-6787.2006.00058.xPubmed Abstract

[19]  Lewis S2007Toward a general theory of indifference to research-based evidence.J Health Serv Res Policy12316672doi:10.1258/135581907781543094Pubmed Abstract

[20]  McQueen DV2001Strengthening the evidence base for health promotion.Health Promot Int1632618doi:10.1093/heapro/16.3.261Pubmed Abstract

[21]  Green JTones K1997Towards a secure evidence base for health promotion.J Public Health Med211339

[22]  Speller VLearmonth AHarrison D1997The search for evidence of effective health promotion.BMJ3153613
Pubmed Abstract

[23]  Health Outcomes International Pty Ltd in association with National Centre in HIV Epidemiology and Clinical Research and Centre of Health Economics. York University. Return on investment in needle and syringe programs in Australia report. Canberra: Commonwealth Department of Health and Ageing; 2002.

[24]  National Centre in HIV Epidemiology and Clinical Research. Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia. Canberra: Australian Government Department of Health and Ageing; 2009.

[25]  Sorensen JLCopeland AL2000Drug abuse treatment as an HIV prevention strategy: a review.Drug Alcohol Depend591731doi:10.1016/S0376-8716(99)00104-0Pubmed Abstract

[26]  Sullivan LEMetzger DSFudala PJFiellin DA2005Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.Addiction1001508doi:10.1111/j.1360-0443.2004.00963.xPubmed Abstract

[27]  Gowing LRFarrell MBornemann RSullivan LEAli RL2006Brief report. Methadone treatment of injecting opioid users for prevention of HIV infection.J Gen Intern Med211935Pubmed Abstract

[28]  Sullivan LEMoore BAChawarski MCPantalon MVBarry DO’Connor PGet al.2008Buprenorphine/naloxone treatment in primary care is associated with decreased HIV risk behaviors.J Subst Abuse Treat3518792doi:10.1016/j.jsat.2007.08.004Pubmed Abstract

[29]  Serpelloni GCarriere MPRezza GMorganti SGomma MBinkin N1994Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-controlled study.AIDS Care621520doi:10.1080/09540129408258632Pubmed Abstract

[30]  Williams ABMcNelly EAWilliams AED’Aquila RT1992Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users.AIDS Care43541doi:10.1080/09540129208251618Pubmed Abstract

[31]  Metzger DSWoody GEMcLellan ATO’Brien CPDruley PNavaline Het al.1993Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up.J Acquir Immune Defic Syndr6104956Pubmed Abstract

[32]  Moss ARVranizan KGorter RBachetti PWatters JOsmond D1994HIV seroconversion in intravenous drug users in San Francisco 1985–90.AIDS822331doi:10.1097/00002030-199402000-00010Pubmed Abstract

[33]  Garfein RSGolub ETGreenberg AEHagan HHanson DLHudson SMet al.2007A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users.AIDS2114192332doi:10.1097/QAD.0b013e32823f9066

[34]  Latka MHHagan HKapadia FGolub ETBonner SCampbell JVet al.2008A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C.Am J Public Health9885361doi:10.2105/AJPH.2007.113415Pubmed Abstract

[35]  Wodak AMcLeod L2008The role of harm reduction in controlling HIV among injecting drug users.AIDS22Suppl. 2S6779doi:10.1097/01.aids.0000327439.20914.33

[36]  Nadelmann EA1989Drug prohibition in the United States: costs, consequences, and alternatives.Science245492193947doi:10.1126/science.2772647Pubmed Abstract

[37]  Moore TJ. What is Australia’s ‘drug budget’? The policy mix of illicit drug-related government expenditure in Australia. Drug Policy Modelling Project Monograph 1. Melbourne: Turning Point Alcohol and Drug Centre; 2005.

[38]  Bluthenthal RNLorvick JKral AHErringer EAKahn JG2008Collateral damage in the war on drugs: HIV risk behaviours among injection drug users.Int J Drug Policy102538doi:10.1016/S0955-3959(98)00076-0

[39]  Maher LDixon D1999Policing and public health: law enforcement and harm minimization in a street-level drug market.Br J Criminol39488512doi:10.1093/bjc/39.4.488

[40]  Maher LLi JJalaludin BWand HJayasuriya RDixon Det al.2007Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia.Drug Alcohol Depend8924450doi:10.1016/j.drugalcdep.2007.01.001Pubmed Abstract

[41]  Kerr TSmall WWood E2005The public health and social impacts of drug market enforcement: a review of the evidence.Int J Drug Policy1621020doi:10.1016/j.drugpo.2005.04.005

[42]  Pollini RABrouwer KCLozada RMRamos RCruz MFMagis-Rodriguez Cet al.2008Syringe possession arrests are associated with receptive syringe sharing in two Mexico–US border cities.Addiction10311018doi:10.1111/j.1360-0443.2007.02051.x

[43]  Friedman SRCooper HLFTempalski BKeem MFriedman RFlom Pet al.2006Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas.AIDS201939doi:10.1097/01.aids.0000196176.65551.a3

[44]  Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional and national coverage. Lancet 2010; 375: 1014–28. Pubmed Abstract

[45]  National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2009. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2009. Available at: (Accessed 4 March 2010.)

[46]  Kwon JAIversen JMaher LLaw MWilson D2009The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: A model-based analysis.J Acquir Immune Defic Syndr514629doi:10.1097/QAI.0b013e3181a2539aPubmed Abstract

[47]  Higgs PYohannes KHellard MMaher L2009Factors influencing a self limiting HIV outbreak among ethnic Vietnamese injecting drug users in Melbourne, Australia.Qual Health Res191690701doi:10.1177/1049732309352470Pubmed Abstract

[48]  Butler T, Milner L. The 2001 New South Wales Inmate Health Survey. Sydney: Corrections Health Service; 2003.

[49]  Jürgens RBall AVerster A2009Interventions to reduce HIV transmission related to injecting drug use in prison.Lancet Infect Dis95766doi:10.1016/S1473-3099(08)70305-0Pubmed Abstract

[50]  Stimson GV, O’Hare P. Harm reduction: moving through the third decade. [editorial] Int J Drug Policy 2010; 21(2): 91–3. Pubmed Abstract

[51]  Maher LCoupland HMusson R2007Scaling up HIV treatment, care and support for injecting drug users in Vietnam.Int J Drug Policy18296305doi:10.1016/j.drugpo.2006.12.006Pubmed Abstract

Full Text PDF (73 KB) Export Citation